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The folate receptor is an attractive target for selective tumor delivery of liposomal doxorubicin (DXR) because it is abundantly
expressed in a large percentage of tumors. This study examined the eﬀect of polyethylene glycol (PEG) spacer length and
folate ligand density on the targeting ability of folate-modiﬁed liposomes. Liposomes were modiﬁed with folate-derivatized
PEG-distearoylphosphatidylethanolamine with PEG molecular weights of 2000, 3400, or 5000. The association of DXR-loaded
liposomes with KB cells, which overexpress the folate receptor, was evaluated by ﬂow cytometry at various ratios of folate
modiﬁcation. A low ratio of folate modiﬁcation with a suﬃciently long PEG chain showed the highest folate receptor-mediated
association with the cells, but did not show the highest in vitro cytotoxicity. DXR release from folate-modiﬁed liposomes in
endosomes might be diﬀerent. These ﬁndings will be useful for designing folate receptor-targeting carriers.
1.Introduction
Antitumor drug delivery systems with nanoscopic dimen-
sions have received much attention due to their unique accu-
mulationbehavioratthetumorsite.Variousnanoparticulate
carriers such as liposomes, polymer conjugates, polymeric
micelles, and nanoparticles are utilized for selective delivery
of various anticancer drugs to tumors in a passive targeting
manner [1]. However, a more eﬀective and active targeting
system is needed to enhance the uptake of drugs using
nanocarriers into cancerous cells at the tumor site.
Receptor-mediated endocytosis pathways have been
exploited for tumor-speciﬁc targeting of nanocarriers and
intracellular delivery of their contents. Modiﬁcation of
carrierswithaliganddirectedtoanoverexpressedreceptorin
cancer cells can improve selectivity and facilitate the move-
ment of carriers into the intracellular compartment. One
suchcandidateligandisfolicacidbecausethefolatereceptor-
α is overexpressed in a number of human tumors, including
ovarian, lung, brain, head and neck, and breast tumors [2–
4]. Folic acid has been widely employed as a targeting moiety
for various anticancer drugs through covalent conjugation
to anticancer drugs and nanocarriers [5–8]. Liposomes
modiﬁed with folic acid showed selective targeting toward
human carcinomas along with enhancement of doxorubicin
(DXR) cytotoxicity in vitro [9].
Ligand density per drug carrier and spacer length
are important in designing suitable carriers for targeting.
However, the optimal ligand density on liposomes is contro-
versial. Diﬀerentdensities offolatein liposomes (ligand/total
lipid molar ratio) ranging between 0.01% and 1.0% have
been reported in the literature as suﬃcient to promote
liposome binding to the folate receptor on cells [10–12].
These diﬀerences may be related to the accessibility of the
folate ligand [13] or to the diﬀerences in the polyethylene
glycol (PEG)-folate chemical linkage [14]. Because PEGy-
lated liposomes, called sterically stabilized liposomes, reduce
the association of liposome-modiﬁed ligands with their
receptors by steric hindrance of the PEG polymer [13], we
used non-PEGylated liposomes to examine the optimum
number and spacer length of the targeting ligand.
In this study, folate-mediated association of DXR-loaded
liposomes with human oral carcinoma KB cells, which
overexpress the folate receptor, was evaluated in terms of
PEG spacer length and the ratio of modiﬁcation with the
folate ligand. Enhanced association of DXR in KB cells was2 Journal of Drug Delivery
shownwithanextremelylowratiooffolatemodiﬁcationand
as u ﬃciently long PEG spacer length, but high cytotoxicity of
DXR was observed with a high ratio of folate modiﬁcation.
2.MaterialsandMethods
2.1. Materials. Hydrogenated soybean phosphatidylcholine
(HSPC), aminopoly(ethyleneglycol)-distearoylphosphatid-
ylethanolamine (amino-PEG-DSPE, PEG mean molecular
weight of 2000, 3400, and 5000), and methoxy-PEG5000-
DSPE (mPEG5000-DSPE) were obtained from NOF Corpo-
ration (Tokyo, Japan). Cholesterol (Ch), doxorubicin (DXR)
hydrochloride, folic acid, and HPLC-grade acetonitrile
were purchased from Wako Pure Chemical Industries, Ltd.
(Osaka, Japan). Folate-derivatized PEG-DSPE (F-PEG2000-,
F-PEG3400-, and F-PEG5000-DSPE), which are conjugates
of folic acid and amino-PEG-DSPE, were synthesized as
reported previously [13, 15]. Ionophore A23187 and 1,1 -
dioctadecyl-3,3,3 ,3 -tetramethylindocarbocyanine perchlo-
rate (DiI) were purchased from Sigma (St. Louis, MO,
USA) and Lambda Probes and Diagnostics (Graz, Austria),
respectively. Folate-deﬁcient RPMI 1640 medium and fetal
bovine serum (FBS) were obtained from Invitrogen Corp.,
(Carlsbad, CA, USA). Other reagents used in this study were
reagent grade.
2.2. Preparation of Folate-Modiﬁed Liposomes. Liposomes
were prepared from HSPC/Ch (55/45mol/mol). All lipids
were dissolved in chloroform, which was removed by evapo-
ration. Lipophilic ﬂuorescent marker DiI-labeled liposomes
were prepared by the same procedure, but with the addition
of DiI (0.4mol% of total lipid) to the lipid mixture and
without DXR loading. The ﬁlm was hydrated with MgSO4
aqueous solution (300mM, adjusted to pH 3.5 with HCl)
and sonication. The resulting mean diameter of liposomes
was about 130nm, as determined by the dynamic light
scattering method (ELS-800; Otsuka Electronics Co., Ltd.,
Osaka, Japan) at 25◦C after diluting the liposome suspension
with water.
DXR was encapsulated into liposomes using the
ionophore-mediated loading method [16, 17]. The MgSO4
gradient was formed by exchange of the external solution
with sucrose buﬀer (300mM sucrose, 20mM HEPES, and
15mM EDTA; pH 7.4) by gel ﬁltration chromatography.
Subsequent addition of ionophore A23187 to the liposome
dispersionresultsintheoutwardmovementof1metalcation
in exchange for 2 protons, thus establishing a transmem-
brane pH gradient. A23187 was used at a concentration of
0.1μg/μmol lipid and liposomes were incubated with the
ionophore at 60◦C for 5min prior to the addition of drug.
DXR was then added to the liposomes at a ﬁnal drug-
to-lipid ratio of 0.2:1 (wt/wt) and incubated at 60◦Cf o r
20min.
For comparison of loading procedures, DXR was encap-
sulatedinliposomesbythepHgradientmethod[18].Brieﬂy,
the lipid ﬁlm was hydrated with citrate buﬀer (300mM; pH
4.0) and sonicated. After the external pH was adjusted to 7.4,
liposomes were incubated with DXR (drug:lipid = 0.2:1,
wt/wt) at 60◦C for 20min.
The folate ligand was inserted into preformed liposomes
by the postinsertion technique [19]. Brieﬂy, liposomes
(DXR-loaded or DiI-labeled) were incubated with an aque-
ous dispersion of F-PEG-DSPE (from 0.01 to 1mol% of
total lipid) at 60◦C for 1h. In the case of unmodiﬁed
liposomes (NF-L), water was added instead of F-PEG-DSPE
solution. Liposomes modiﬁed with F-PEG2000-, F-PEG3400-,
F-PEG5000-, or mPEG5000-DSPE will henceforth be desig-
nated as F2-L, F3-L, F5-L, and M5-L, respectively. After
heating, the liposomes were cooled to room temperature.
The suspension was then passed through a Sephadex G-
50 column to remove any leaked DXR and unincorporated
folate ligand. DXR loading eﬃciency was determined and
signiﬁcant DXR leakage was not observed with incubation
of F-PEG-DSPE at these concentrations. DXR concentration
was determined by measuring absorbance at 480nm (UV-
1700 Phamaspec, Shimadzu Corp., Kyoto, Japan).
2.3. In Vitro Assay for Drug Retention. The release of drug
from the liposomes in phosphate-buﬀered saline (PBS, pH
7.4 or 5.0) was monitored by a dialysis method. The dialysis
was done at 37◦C using seamless cellulose tube membranes
(Spectrum, Houston, TX, USA) with a molecular weight
cutoﬀ of 300,000Da and PBS as the sink solution. The initial
concentrationofDXR-loadedliposomeswas0.2mg/mL.The
sample volume in the dialysis bag was 1mL, and the sink
volume was 100mL. The concentration of drug was analyzed
at various times points during dialysis.
2.4. Cellular Association of Liposomes Determined by Flow
Cytometry. KB cells were obtained from the Cell Resource
Center for Biomedical Research, Tohoku University (Miyagi,
Japan). The cells were cultured in folate-deﬁcient RPMI
1640mediumwith10%heat-inactivatedFBSandkanamycin
sulfate (50μg/mL) in a humidiﬁed atmosphere containing
5% CO2 at 37◦C.
The cells were prepared by plating 3 × 105 cells/well
in a 12-well culture plate 1 day before the assay. The
cells were incubated with DXR-loaded liposomes or DiI-
labeled liposomes containing 20μg/mL DXR or 100μg/mL
lipid diluted in 1mL of serum-free medium for 2h or
the indicated time at 37◦C. For free ligand competition
studies, 1mM folic acid was added to the medium. After
incubation, the cells were washed with cold PBS (pH 7.4),
detached with 0.02% EDTA-PBS, and then suspended in
PBS containing 0.1% bovine serum albumin and 1mM
EDTA. The suspended cells were directly introduced into
a FACSCalibur ﬂow cytometer (Becton Dickinson, San
Jose, CA) equipped with a 488nm argon ion laser. Data
for 10,000 ﬂuorescent events were obtained by recording
forwardscatter,sidescatter,and585/42nmﬂuorescence.The
autoﬂuorescence of cells incubated with serum-free medium
without drug for 2h was used as the control.
2.5. Cytotoxicity of Liposomes in KB Cells. KB cells were
incubated with DXR-loaded liposomes (20μg/mL) for 2h.
After incubation, the cells were washed with cold PBS
and cultured in fresh medium for 48h. Cytotoxicity was
determined using the WST-8 assay (Dojindo Laboratories,Journal of Drug Delivery 3
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Figure 1: DXR release proﬁle of liposomes loaded by the
MgSO4/ionophore method () and pH gradient method using
citrate buﬀer ()i nP B S( p H7 . 4 )a t3 7 ◦C. Each value represents
the mean ± SD (n = 3).
Kumamoto, Japan) based on enzymatic reduction of a
tetrazolium salt, WST-8, to water-soluble formazan. The
number of viable cells was then determined by absorbance
at 450nm.
3. Results andDiscussion
3.1. Characterization of DXR-Loaded and Folate-Modiﬁed
Liposomes. For eﬃcient drug delivery to the target site,
drugs should be stably entrapped in liposomes. In this
study, an ionophore-mediated pH gradient method utilizing
MgSO4 was applied to load DXR into liposomes because
this method can eﬀectively encapsulate drugs [17]. More
than 95% of DXR was incorporated in liposomes using this
system at a drug-to-total lipid ratio of 1:5 (wt:wt). The
drug retention in the liposomes was examined by incubation
in PBS (pH 7.4) at 37◦C. For comparison, DXR-liposomes
loaded by the remote loading method using citrate buﬀer
were used. As shown in Figure 1, DXR-liposomes loaded
usingMgSO4 showedsigniﬁcantlylowerDXRleakageduring
the 72-h incubation compared with those loaded using
citrate buﬀer, indicating that the DXR-liposomes produced
by the ionophore/MgSO4 loading method were more stable
than those produced by the pH gradient method. Therefore,
we applied the ionophore/MgSO4 method to load DXR
into liposomes for evaluation of folate receptor-targeted
liposomes.
The average particle size of liposomes used in this study
was approximately 130nm, and the folate modiﬁcation did
not change the sizes of liposomes. More than 80% of folate
ligand was inserted in liposomes at each ratio, which was
conﬁrmed after the separation of folate-modiﬁed liposomes
by ultracentrifugation (100,000 × g, 1h, 4◦C).
3.2. Eﬀects of Spacer Length and Modiﬁcation Ratio of F-
PEG-DSPE on Liposome Association with KB Cells. In this
study, the cellular association of folate-modiﬁed liposomes
was evaluated in KB cells with respect to PEG spacer length
and modiﬁcation ratio by ﬂow cytometry based on DXR
ﬂuorescence (Figure 2(a)) and DiI-labeled liposomes (Fig-
ure 2(b)). Folate modiﬁcation with F-PEG2000-, F-PEG3400-,
or F-PEG5000-DSPE (F2-, F3-, and F5-L) at 0.03 to 1.0mol%
enhanced the cellular association compared to that of
unmodiﬁed liposomes (NF-L), indicating that diﬀerences in
the density and PEG spacer length of folate ligands resulted
in diﬀerent liposome associations with KB cells. The highest
association of liposomes was observed with 0.03mol% folate
modiﬁcation with the PEG5000 spacer, which was 1.7-fold
and 160-fold higher than that of unmodiﬁed liposomes by
measurement of DXR and DiI, respectively (Figure 2(a)
inset and Figure 2(b)). The large discrepancy in the value
might be due to the diﬀerence of distribution of DXR
and DiI in liposomes, that is, DXR was entrapped in the
water phase of liposomes, but DiI was incorporated in
the liposomal membrane. Both the drug incorporated into
liposomes and the lipid membrane of liposomes revealed a
similar enhancement in association, suggesting that the DXR
was associated in the liposomal form, not as drug released
from liposomes.
Next, we conﬁrmed whether folate might mediate cellu-
lar association with KB cells by mPEG-DSPE modiﬁcation
and free ligand competition (Figure 3). F5-L with 0.03mol%
folate modiﬁcation showed higher cellular association than
NF-L and M5-L (0.03mol% mPEG-DSPE modiﬁcation)
did. Furthermore, the cellular association of F5-L could be
blocked by 1mM free folic acid and reduced to the level of
NF-L. These results indicated that enhancement was due to
folate-mediated cellular association.
The eﬀect of incubation time on the cellular associa-
tion of liposomes was then examined (Figure 4). As the
incubation time increased, cellular associations increased
and higher association was observed with F5-L modiﬁed
at 0.03mol% than at 0.3mol%. Cellular association of
liposomes modiﬁed at 0.3mol% seemed to be saturated
after a 2-h incubation. It has been reported that the folate
receptor recycling system is downregulated as a result of
satisfactionofthecellularfolaterequirement[11].Therefore,
liposomes modiﬁed with more folate ligands would lead
to a larger intracellular folate content than those with
fewer targeting ligands. Our data showed that liposomes
containing fewer folate ligands per liposome had higher
association eﬃciencies compared to liposomes containing
large numbers of folate ligands per liposome. As a result,
liposomes with minimal folate ligands may be eﬃcient in
enhancing drug accumulation in cells.
3.3. Eﬀect of Folate Modiﬁcation Ratio on Cytotoxicity. The
eﬀect of the folate modiﬁcation ratio on cytotoxicity in KB
cells was evaluated using the WST-8 assay (Figure 5). Cell
viability was compared with untreated control. All folate-
modiﬁed liposomes showed higher cytotoxicity than NF-L.
The cytotoxicity of F5-L was sharply enhanced from 0mol%
to 0.03mol% folate modiﬁcation, which correlated with4 Journal of Drug Delivery
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Figure 2: Association of folate-modiﬁed liposomes with KB cells
with2-hincubationwasdeterminedbyﬂuorescenceofDXR-loaded
liposomes (a) and DiI-labeled liposomes (b) using ﬂow cytometry.
(a) Folate modiﬁcation from 0.03 to 1.0mol% of F2-, F3-, and
F5-PEG-DSPE. Inset: F5-PEG-DSPE modiﬁcation from 0.01 to
0.3mol%. (b) Folate modiﬁcation from 0.01 to 0.3mol% of F2-,
F3-, and F5-PEG-DSPE.
M5-L
(0.03 mol%)
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(0.03 mol%)
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Mean ﬂuorescence of DXR-loaded liposome
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Figure 3: Association of DXR-loaded liposomes with KB cells
with 1-h incubation was determined by ﬂow cytometry. Cells were
incubated with each liposome in folate-free medium or medium
containing 1mM folic acid.
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Figure 4: Cellular association of DXR-loaded liposomes with time
was determined by ﬂow cytometry. KB cells were incubated with
F5-L modiﬁed at 0.03 or 0.3mol% or without folate modiﬁcation
(NF-L).
the result of their cellular associations (Figure 2). However,
modiﬁcation with concentrations greater than 0.03mol%
gently enhanced the cytotoxicity, which did not correlate
with cellular associations. As in the case of F5-L, 0.3mol%
folate-modiﬁed F2-L and F3-L showed higher cytotoxicity
than with 0.03mol% modiﬁcation.Journal of Drug Delivery 5
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Figure 5: Cytotoxicity of DXR-loaded liposomes against KB cells.
Cells were incubated with each liposome at a DXR concentration
of 20μg/mL for 2h, then in fresh medium for 48h. Each value
represents the mean ± SD (n = 3).
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Figure 6: DXR release proﬁle of folate-modiﬁed liposomes (F5-
L) in PBS (pH 5.0) at 37◦C. Each point represents the mean of 2
experiments.
The release of free drug from liposomes is involved
in cytotoxicity or antitumor activity [20, 21]. Thus, we
measured DXR release from liposomes with diﬀerent mod-
iﬁcation ratios at pH 5.0, which resembled endosome con-
tent (Figure 6). Liposomes with high modiﬁcation showed
slightly higher drug release than those with low or no
modiﬁcation, although the release from all formulations was
very low. Because DXR was stably loaded in the liposome
using ionophore/MgSO4,i tm a yb ed i ﬃcult to evaluate drug
release diﬀerences under these conditions. Taken together,
the enhanced cytotoxicity might reﬂect changes in drug
release from liposomes by folate modiﬁcation. Further
evaluation of folate-modiﬁed drug carriers will be needed to
optimize cellular association, cytotoxicity, and/or antitumor
eﬀects.
4. Conclusions
In this study, the eﬀects of PEG spacer length and ligand
densityonfolatereceptor-targetedliposomeswereevaluated.
Al o wr a t i oo ff o l a t em o d i ﬁ c a t i o nw i t has u ﬃciently long
PEG chain (F-PEG5000-DSPE) increased folate receptor-
mediated association, but a high ratio of folate modiﬁcation
enhanced in vitro cytotoxicity. This information will be
useful for designing folate receptor-targeting carriers.
Acknowledgments
ThisworkwassupportedinpartbyaGrant-in-AidforYoung
Scientists (B) from the Ministry of Education, Culture,
Sports, Science and Technology of Japan and by the Open
ResearchCenterProject.TheauthorswouldliketothankMr.
Ken Kajihara for his assistance in the experimental work.
References
[1] K. Cho, XU. Wang, S. Nie, Z. Chen, and D. M. Shin, “Ther-
apeutic nanoparticles for drug delivery in cancer,” Clinical
Cancer Research, vol. 14, no. 5, pp. 1310–1316, 2008.
[2] S. D. Weitman, R. H. Lark, L. R. Coney et al., “Distribution
of the folate receptor GP38 in normal and malignant cell lines
and tissues,” Cancer Research, vol. 52, no. 12, pp. 3396–3401,
1992.
[3] M. Wu, W. Gunning, and M. Ratnam, “Expression of folate
receptor type α in relation to cell type, malignancy, and dif-
ferentiation in ovary, uterus, and cervix,” Cancer Epidemiology
Biomarkers and Prevention, vol. 8, no. 9, pp. 775–782, 1999.
[ 4 ]N .P a r k e r ,M .J .T u r k ,E .W e s t r i c k ,J .D .L e w i s ,P .S .L o w ,
and C. P. Leamon, “Folate receptor expression in carcinomas
and normal tissues determined by a quantitative radioligand
binding assay,” Analytical Biochemistry, vol. 338, no. 2, pp.
284–293, 2005.
[5] S. Wang and P. S. Low, “Folate-mediated targeting of anti-
neoplastic drugs, imaging agents, and nucleic acids to cancer
cells,” Journal of Controlled Release, vol. 53, no. 1–3, pp. 39–48,
1998.
[ 6 ]X .Q .P a n ,H .W a n g ,a n dR .J .L e e ,“ A n t i t u m o ra c t i v i t y
of folate receptor-targeted liposomal doxorubicin in a KB
oral carcinoma murine xenograft model,” Pharmaceutical
Research, vol. 20, no. 3, pp. 417–422, 2003.
[ 7 ]W .A .H e n n e ,D .D .D o o r n e w e e r d ,A .R .H i l g e n b r i n k ,S .A .
K u l a r a t n e ,a n dP .S .L o w ,“ S y n t h e s i sa n da c t i v i t yo faf o l a t e
peptide camptothecin prodrug,” Bioorganic and Medicinal
Chemistry Letters, vol. 16, no. 20, pp. 5350–5355, 2006.
[8] Y. Bae, N. Nishiyama, and K. Kataoka, “In vivo antitu-
mor activity of the folate-conjugated pH-sensitive polymeric
micelle selectively releasing adriamycin in the intracellular
acidic compartments,” Bioconjugate Chemistry, vol. 18, no. 4,
pp. 1131–1139, 2007.6 Journal of Drug Delivery
[9] R. J. Lee and P. S. Low, “Folate-mediated tumor cell targeting
of liposome-entrapped doxorubicin in vitro,” Biochimica et
Biophysica Acta, vol. 1233, no. 2, pp. 134–144, 1995.
[10] J. A. Reddy, C. Abburi, H. Hoﬂand et al., “Folate-targeted,
cationic liposome-mediated gene transfer into disseminated
peritoneal tumors,” Gene Therapy, vol. 9, no. 22, pp. 1542–
1560, 2002.
[11] J. M. Saul, A. Annapragada, J. V. Natarajan, and R. V.
Bellamkonda, “Controlled targeting of liposomal doxorubicin
via the folate receptor in vitro,” Journal of Controlled Release,
vol. 92, no. 1-2, pp. 49–67, 2003.
[12] H. Shmeeda, L. Mak, D. Tzemach, P. Astrahan, M. Tarshish,
and A. Gabizon, “Intracellular uptake and intracavitary tar-
geting of folate-conjugated liposomes in a mouse lymphoma
model with up-regulated folate receptors,” Molecular Cancer
Therapeutics, vol. 5, no. 4, pp. 818–824, 2006.
[13] A. Gabizon, A. T. Horowitz, D. Goren et al., “Targeting folate
receptor with folate linked to extremities of poly(ethylene
glycol)-grafted liposomes: in vitro studies,” Bioconjugate
Chemistry, vol. 10, no. 2, pp. 289–298, 1999.
[14] C.P.LeamonandJ.A.Reddy,“Folate-targetedchemotherapy,”
AdvancedDrugDeliveryReviews,vol.56,no.8,pp.1127–1141,
2004.
[15] T. Shiokawa, Y. Hattori, K. Kawano et al., “Eﬀe c to fp o l y e t h y -
leneglycollinkerchainlengthoffolate-linkedmicroemulsions
loading aclacinomycln a on targeting ability and antitumor
eﬀe c ti nv i t r oa n di nv i v o , ”Clinical Cancer Research, vol. 11,
no. 5, pp. 2018–2025, 2005.
[16] B.C.L.Cheung, T.H.T. Sun,J.M.Leenhouts, andP. R.Cullis,
“Loading of doxorubicin into liposomes by forming Mn-drug
complexes,” Biochimica et Biophysica Acta, vol. 1414, no. 1-2,
pp. 205–216, 1998.
[17] S. A. Abraham, K. Edwards, G. Karlsson et al., “Formation
of transition metal-doxorubicin complexes inside liposomes,”
BiochimicaetBiophysicaActa,vol.1565,no.1,pp.41–54,2002.
[18] X. Li, D. J. Hirsh, D. Cabral-Lilly et al., “Doxorubicin physical
state in solution and inside liposomes loaded via a pH
gradient,” Biochimica et Biophysica Acta, vol. 1415, no. 1, pp.
23–40, 1998.
[19] P. S. Uster, T. M. Allen, B. E. Daniel, C. J. Mendez, M. S.
Newman, and G. Z. Zhu, “Insertion of poly(ethylene glycol)
derivatized phospholipid into pre-formed liposomes results in
prolonged in vivo circulation time,” FEBS Letters, vol. 386, no.
2-3, pp. 243–246, 1996.
[20] M. J. Kirchmeier, T. Ishida, J. Chevrette, and T. M. Allen,
“Correlations between the rate of intracellular release of endo-
cytosed liposomal doxorubicin and cytotoxicity as determined
byanewassay,”JournalofLiposomeResearch,vol.11,no.1,pp.
15–29, 2001.
[21] M. J. W. Johnston, S. C. Semple, S. K. Klimuk et al., “Ther-
apeutically optimized rates of drug release can be achieved
by varying the drug-to-lipid ratio in liposomal vincristine
formulations,” Biochimica et Biophysica Acta, vol. 1758, no. 1,
pp. 55–64, 2006.